An international study published in the New England Journal of Medicine provides hope for chronic lymphocytic leukemia (CLL) ...

Leukemic stem cells (LSCs) and stemness signatures contribute to minimal residual disease in patients with acute myeloid ...

Researchers observed an increase in both CXCR4 and CD5 levels as the cells progressed to later stages of the cell cycle, particularly in the S/G2/M phases.

University of Queensland research using natural killer cells may lead to the first new treatment for a devastating childhood ...

(AML) patients across both original and expansion cohorts remain in complete remission (CR), with a median follow-up of 20.1 ...

A new case report was published in Volume 16 of Oncotarget on February 5, 2025, titled “A case report of donor cell–derived ...

As the nation's largest organization serving the critical needs of blood cancer patients, we are alarmed by recent actions ...

BioSkryb Genomics, a Durham company focused on single-cell and ultra-low input multiomics, has introduced a new service called ResolveSEQ MRD, which allows more detailed classification and ...

A research team has made a major discovery on how the CUL5 gene affects CAR-T cell therapy, an advanced cancer therapy. The study reveals that reducing the activity of the CUL5 gene helps CAR-T cells ...

Van Andel Institute researchers discovered that cancer risk may be determined before birth due to distinct epigenetic states ...

Patients treated in community settings were more likely to be older, less likely to be White, and had worse survival rates, ...

TC BioPharm's Phase 2B trial of TCB008 in AML progresses as the first Cohort B patient completes dosing. Enrollment continues, with data expected in 2025.